Clinical trial
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With…
NCT00307437 · Centocor Research & Development, Inc., Industry · Completed
Key facts
| NCT number | NCT00307437 |
|---|---|
| Title | A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis |
| Official title | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis. |
| Lead sponsor | Centocor Research & Development, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Placebo, Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg |
| Enrollment | 1,230 |
| Start date | May 1, 2005 |
| Primary completion | Dec 1, 2006 |
| Completion | Oct 1, 2011 |
| First posted | Mar 28, 2006 |
| Last update posted | Jan 24, 2013 |
| Countries | Austria, Canada, France, Germany, Switzerland, United Kingdom, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: